Impel Pharmaceuticals (NASDAQ:IMPL) Price Target Lowered to $14.00 at Guggenheim

Impel Pharmaceuticals (NASDAQ:IMPLGet Rating) had its price target decreased by Guggenheim to $14.00 in a report released on Monday, Stock Target Advisor reports.

IMPL has been the topic of several other reports. Cowen dropped their price objective on Impel Pharmaceuticals to $40.00 in a report on Thursday, November 17th. Wedbush lowered Impel Pharmaceuticals from an outperform rating to a neutral rating and dropped their price objective for the company from $24.00 to $5.00 in a report on Tuesday, November 15th. Finally, Jonestrading initiated coverage on Impel Pharmaceuticals in a research report on Wednesday, August 24th. They issued a buy rating and a $26.00 target price on the stock.

Impel Pharmaceuticals Stock Up 1.9 %

Shares of IMPL opened at $2.73 on Monday. The company has a current ratio of 4.97, a quick ratio of 4.54 and a debt-to-equity ratio of 12.07. Impel Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $10.75. The stock’s 50 day moving average is $4.44 and its two-hundred day moving average is $6.69. The firm has a market cap of $64.81 million, a P/E ratio of -0.59 and a beta of 0.04.

Hedge Funds Weigh In On Impel Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of Impel Pharmaceuticals by 11.6% in the second quarter. Goldman Sachs Group Inc. now owns 14,285 shares of the company’s stock valued at $133,000 after acquiring an additional 1,484 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Impel Pharmaceuticals by 746.7% during the third quarter. Tower Research Capital LLC TRC now owns 10,245 shares of the company’s stock worth $50,000 after buying an additional 9,035 shares in the last quarter. BlackRock Inc. lifted its position in Impel Pharmaceuticals by 10.0% during the third quarter. BlackRock Inc. now owns 107,254 shares of the company’s stock worth $523,000 after buying an additional 9,783 shares in the last quarter. State Street Corp lifted its position in Impel Pharmaceuticals by 6.6% during the first quarter. State Street Corp now owns 180,045 shares of the company’s stock worth $1,147,000 after buying an additional 11,107 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Impel Pharmaceuticals during the third quarter worth approximately $64,000. Hedge funds and other institutional investors own 63.57% of the company’s stock.

About Impel Pharmaceuticals

(Get Rating)

Impel Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.

Recommended Stories

Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.